EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study

Tomasz Wojciech Rutkowski iD, Agata Kurczyk iD, Katarzyna Drosik-Rutowicz, Dorota Kiprian, Izabella Dębicka, Ewa Sierko, Monika Konopka-Filippow, Joanna Kaźmierska, Monika Łukasiewicz-Grella, Diana Cząstkiewicz-Trawińska, Izolda Mrochem-Domin, Iwona Ryniewicz-Zander und 10 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35248 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Tomasz Wojciech Rutkowski und 21 weiteren Autor:innen. Beteiligte Einrichtung: Radiation and Clinical Oncology Department and Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of …. Hauptthemen laut MEDLINE: Nivolumab, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local, Head and Neck Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with head and neck squamous cell carcinoma (HNSCC) who have progressed following primary treatment (PT) have a poor prognosis. In this group, nivolumab has been demonstrated to significantly improve outcomes. This study presents the efficacy of nivolumab in Polish patients with recurrent and/or metastatic (R/M) HNSCC using real‐world data. The analyzed group consisted of 324 adult patients with R/M HNSCC following platinum‐based therapy. Patients were divided into 3 groups based on the time from completion of PT to nivolumab initiation (tPT‐ N ): within 6 months (refractory), between 6 and 24 months (sensitive, tPT‐ N ≤24), and beyond 24 months (sensitive, tPT‐ N >24). Survival analysis and the Cox proportional hazards model were performed to evaluate how various risk factors affect patient outcomes. The 1‐year and 2‐year overall survival (OS) was 19.1%, 6.1%, 30.7%, 9.4%, and 45.7%, 29.1% in refractory, sensitive tPT‐ N ≤24, sensitive tPT‐ N >24 patients, respectively and was higher for both sensitivity groups vs. refractory ( p = .004) and for sensitive tPT‐ N >24 versus refractory and sensitive tPT‐ N ≤24 ( p 24 (HR = 0.53, p = .001) and nasopharyngeal cancer on OS (HR = 0.20, p = .008). Conversely, female sex was identified as an unfavorable factor for OS (HR = 1.48, p = .020). In our study, we established that the benefit of nivolumab increases with the increasing tPT‐ N . The probability of death is significantly lower in male patients and patients with nasopharyngeal cancer regardless of tPT‐ N .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabSquamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedAgedPolandAdultAntineoplastic Agents, ImmunologicalAged, 80 and overRetrospective StudiesNeoplasm MetastasisPrognosis

Stichwörter der Autor:innen

immunotherapynivolumabrecurrent or metastatic head and neck cancer

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Radiation and Clinical Oncology Department and Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
  • Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Department of Clinical Oncology, Lower Silesian Oncology, Pulmonology and Hematology Center, Wrocław, Poland.
  • Department of Radiation Therapy, Maria-Sklodowska-Curie Oncology Center, Bialystok, Poland.
  • Department of Oncology, Medical University of Bialystok, Bialystok, Poland.
  • Greater Poland Cancer Center, Department of Electroradiology, University of Medical Sciences, Poznań, Poland.

ORCID-Profile: Tomasz Wojciech Rutkowski, Agata Kurczyk

Zitieren

APA

Rutkowski, T. W., Kurczyk, A., Drosik-Rutowicz, K., Kiprian, D., Dębicka, I., Sierko, E., Konopka-Filippow, M., Kaźmierska, J., Łukasiewicz-Grella, M., Cząstkiewicz-Trawińska, D., Mrochem-Domin, I., Ryniewicz-Zander, I., Borysiewicz, Z., Chmielowska, E., Jasiówka, M., Źrebiec-Figura, M., Karpińska, A., Pacholczak-Madej, R., Leś, D., …, & Składowski, K. (2025). Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study. International Journal of Cancer. https://doi.org/10.1002/ijc.35248

Vancouver

Rutkowski TW, Kurczyk A, Drosik-Rutowicz K, Kiprian D, Dębicka I, Sierko E, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study. International Journal of Cancer. 2025. doi:10.1002/ijc.35248

BibTeX
@article{Rutkowski2025,
  author = {Rutkowski, Tomasz Wojciech and Kurczyk, Agata and Drosik-Rutowicz, Katarzyna and Kiprian, Dorota and Dębicka, Izabella and Sierko, Ewa and Konopka-Filippow, Monika and Kaźmierska, Joanna and Łukasiewicz-Grella, Monika and Cząstkiewicz-Trawińska, Diana and Mrochem-Domin, Izolda and Ryniewicz-Zander, Iwona and Borysiewicz, Zuzanna and Chmielowska, Ewa and Jasiówka, Marek and Źrebiec-Figura, Monika and Karpińska, Agnieszka and Pacholczak-Madej, Renata and Leś, Dominika and Pietruszka, Agnieszka and Łasinska, Izabela and Składowski, Krzysztof},
  title = {Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35248}
}
Kostenlos starten →